about
Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)Fish oil supplements for rheumatoid arthritisNon-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondyloarthritis) and gastrointestinal or liver comorbidityPain management for inflammatory arthritis and gastrointestinal or liver comorbidityCombination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis)Combination therapy for pain management in inflammatory arthritisEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateApplying science in practice: the optimization of biological therapy in rheumatoid arthritis.Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.Hierarchy of Impairment of Spinal Mobility Measures in Ankylosing Spondylitis: Twelve-Year Data.Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative.Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysisWork outcome in persons with musculoskeletal diseases: comparison with other chronic diseases & the role of musculoskeletal diseases in multimorbidity.Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPt- a national health survey.Association of the different types of radiographic damage with physical function in patients with rheumatoid arthritis: analysis of the RAPID trials.Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?A psychometric analysis of outcome measures in peripheral spondyloarthritis.Educational needs and preferences of young European clinicians and physician researchers working in the field of rheumatology.Rheumatology training experience across Europe: analysis of core competences.Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis.Combination therapy for pain management in inflammatory arthritis: a Cochrane systematic review.How do gastrointestinal or liver comorbidities influence the choice of pain treatment in inflammatory arthritis? A Cochrane systematic review.Impact of socioeconomic gradients within and between countries on health of patients with rheumatoid arthritis (RA): lessons from QUEST RA.Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains: a systematic literature review.Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance.European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort.Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review.The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission.Empty Capsids and Macrophage Inhibition/Depletion Increase rAAV Transgene Expression in Joints of Both Healthy and Arthritic Mice.Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression.Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: a systematic literature review and meta-analysis.Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.
P50
Q24186403-9020E093-24F1-45C2-BD9F-8C1351B6B768Q24197686-B76E7EEE-0752-4E1F-A07C-982C0E76F92DQ24201300-615792B9-6F55-4A68-BBC9-6410DA47F2B7Q24203871-E9AF5CAB-2E02-4443-A8E0-7ACC3D134738Q24235302-E17B5561-8C25-4AAA-A06B-EC3A6AA28D66Q24235846-65DCCCC1-6C80-4533-B00D-01774BD355B7Q24236350-9442E87B-3DAC-4F63-9D9E-98339365501CQ26859134-DEE6D893-C06E-4267-8AE6-4568990E058DQ34613898-65034176-D557-4F36-BA93-961362CA6B92Q35084199-02FC18C4-11F4-427F-8EEA-DB57CCDF025CQ35165774-8425BB7D-9B27-422E-B99D-05553BCDFEB0Q35635197-11A9631A-33F7-49E4-9938-4B16D610EDDAQ36096803-9C688A32-4737-432F-90EC-B57F5F9F0B4DQ36215822-67F8D496-30FD-4C54-8ADD-C859F0A6C9B7Q36244835-DB5CCA5D-912C-4A47-BCBE-62FDC0A50DD6Q36302246-9C8F3C96-585C-4DD4-9E06-9FA2C0DE5F49Q36517265-25040A47-41F5-46E8-9C5E-4D122E73C22FQ36709251-E8F0AEC8-6C13-4F38-BB65-7A68E3ABE4F8Q36903420-EE15C1E0-199B-44D3-A258-419D993151BBQ37085650-FE787799-7642-4AD1-8518-5E27C8D2B7E4Q37133730-F4CD468E-9061-4860-A341-D0524D5B1023Q37280698-197F75A8-8C2F-4401-979D-46AA9146DC5FQ37612248-BA1D5404-D847-4A5C-86CF-586F381B0EFCQ37786625-B4107C2E-D72E-41FD-92C3-0E3E714B6A79Q38040073-2D6996FB-038B-4279-8C2C-88C8BCB34161Q38040074-0005D644-EA8C-499B-A638-82C0FD761F5CQ38065452-AEEB7DD2-DFD3-4EE2-A2C7-236CFB0E0097Q38176549-CFF3BE2B-C05E-4F5D-A6B2-93C68264F10FQ38176745-7D2D19AE-4AED-432E-B39F-02EA49EE67FCQ38268302-AE7733CE-3DBB-4668-9FD9-B00416C4A007Q38591235-8D98D1E8-3622-485A-BFC5-9348C95E77CEQ38661777-98D408B8-B59C-4845-944E-2191236F8D85Q38667430-BCE34E65-7695-4C8D-B84A-92655B3CCB76Q38690333-7D9A6577-B552-47F0-9075-D937AF599627Q38719118-5760E062-E1E3-4802-A801-58C795E50BF9Q38788890-36679DBB-3E73-4547-9EC9-064F390BDD51Q38799924-1269B8C1-F21F-4243-A2E1-7BB1E31B526DQ38837923-9B166B83-477E-4457-A021-F89DDF54DF1EQ38971306-FF27316C-8E7C-44A9-B5FE-50340B967A6DQ38972623-FF87C052-5A3F-4DC9-8C5B-C247B957F342
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sofia Ramiro
@ast
Sofia Ramiro
@en
Sofia Ramiro
@es
Sofia Ramiro
@nl
Sofia Ramiro
@pt
Sofia Ramiro
@sl
type
label
Sofia Ramiro
@ast
Sofia Ramiro
@en
Sofia Ramiro
@es
Sofia Ramiro
@nl
Sofia Ramiro
@pt
Sofia Ramiro
@sl
prefLabel
Sofia Ramiro
@ast
Sofia Ramiro
@en
Sofia Ramiro
@es
Sofia Ramiro
@nl
Sofia Ramiro
@pt
Sofia Ramiro
@sl
P106
P21
P31
P496
0000-0002-8899-9087